Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review
暂无分享,去创建一个
C. Zamboglou | S. Akbaba | T. Bostel | V. Murthy | J. Stelmes | E. Vu | D. Zwahlen | T. Sprave | T. Zilli | T. Telkhade | P. Windisch | R. Foerster | A. Buchali | Christina Schroeder | Hongjian Tang
[1] B. Chang,et al. Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.
[2] J. Mathew,et al. Safety and Efficacy of Ultra-hypofractionation in Node-positive Prostate Cancer. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).
[3] A. Sohaib,et al. Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial , 2020, Clinical and translational radiation oncology.
[4] P. Hoskin,et al. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] Ronald C. Chen,et al. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer , 2020, Radiation oncology.
[6] J. Debus,et al. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery , 2020, Strahlentherapie und Onkologie.
[7] H. Minn,et al. Once‐a‐week or every‐other‐day urethra‐sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow‐up results , 2020, Cancer medicine.
[8] M. Scorsetti,et al. Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[9] G. Rodrigues,et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial , 2019, The Lancet. Oncology.
[10] L. Beckman,et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial , 2019, The Lancet.
[11] Jeff Z. Y. Chen,et al. A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis , 2019, Advances in radiation oncology.
[12] A. Kishan,et al. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. , 2019, International journal of radiation oncology, biology, physics.
[13] Hans T. Chung,et al. SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation. , 2019, International journal of radiation oncology, biology, physics.
[14] A. D'Amico,et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] M. Zelefsky,et al. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer. , 2019, International journal of radiation oncology, biology, physics.
[16] D. Dearnaley,et al. Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL) , 2019, International journal of radiation oncology, biology, physics.
[17] Liying Zhang,et al. Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life. , 2018, International journal of radiation oncology, biology, physics.
[18] R. Phurailatpam,et al. Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).
[19] A. Kishan,et al. Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: Preliminary Toxicity Results of a Phase 2 Trial , 2017 .
[20] W. J. Morris,et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.
[21] Matthew R. Cooperberg,et al. Epidemiology of prostate cancer , 2017, World Journal of Urology.
[22] Josephine Kang,et al. Management of high-risk prostate cancer with 5-treatment stereotactic body radiotherapy: Long-term results. , 2017 .
[23] Alison C. Tree,et al. The Role of Hypofractionated Radiotherapy in Prostate Cancer , 2017, Current Oncology Reports.
[24] C. Catton,et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Kedda,et al. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life , 2017, Journal of medical radiation sciences.
[26] V. Kataja,et al. Hypofractionated stereotactic body radiotherapy for localized prostate cancer – first Nordic clinical experience , 2017, Acta oncologica.
[27] A. Katz,et al. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Risk Stratification for Intermediate- and High-Risk Patients , 2016 .
[28] D. Low,et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Hanlon,et al. The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups , 2016, Front. Oncol..
[30] D. Dearnaley,et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.
[31] B. Heijmen,et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[32] S. Formenti,et al. Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure , 2016, Front. Oncol..
[33] C. Reddy,et al. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes. , 2016, International journal of radiation oncology, biology, physics.
[34] S. Mondello,et al. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer , 2016, Technology in cancer research & treatment.
[35] S. Bydder,et al. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry , 2015, Cureus.
[36] N. Nasr,et al. Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer , 2015, Radiation oncology.
[37] Jeff Z. Y. Chen,et al. A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer. , 2015, International journal of radiation oncology, biology, physics.
[38] H. Chao,et al. Stereotactic Ablative Radiotherapy with CyberKnife in the Treatment of Locally Advanced Prostate Cancer: Preliminary Results , 2015, Tumori.
[39] V. Khoo,et al. Prostate stereotactic body radiotherapy—first UK experience. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).
[40] A. Dritschilo,et al. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3) , 2014, Radiation Oncology.
[41] F. Moraes,et al. Hypofractioned radiotherapy in prostate cancer: is it the next step? , 2014, Expert review of anticancer therapy.
[42] P. Cheung,et al. Evolution of Hypofractionated Accelerated Radiotherapy for Prostate Cancer – The Sunnybrook Experience , 2014, Front. Oncol..
[43] Josephine Kang,et al. Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study , 2014, Front. Oncol..
[44] A. Katz,et al. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study , 2014, Radiation Oncology.
[45] Jason Wang,et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[46] A. Tasca,et al. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy , 2013, BMC Urology.
[47] E. Oermann,et al. Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience , 2013, Radiation Oncology.
[48] L. Brady,et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer , 2012, Journal of Radiation Oncology.
[49] M. Parmar,et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial , 2011, The Lancet.
[50] Dong Han Lee,et al. Image-Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer , 2011, Tumori.
[51] C. L. Cutajar,et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.
[52] S. Fosså,et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.
[53] Charles R. Thomas,et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.
[54] M. Parmar,et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.
[55] Joos V Lebesque,et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Daniel W. Miller,et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.
[57] D J Brenner,et al. Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.
[58] L. Verhey,et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. , 1995, International journal of radiation oncology, biology, physics.
[59] R. Werner,et al. Technological quality requirements for stereotactic radiotherapy Expert review group consensus from the DGMPWorking Group for Physics and Technology in Stereotactic Radiotherapy , 2020 .
[60] J. Blasko,et al. American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. , 2017, Brachytherapy.
[61] J. Lebesque,et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[62] S B Malkowicz,et al. Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .